<DOC>
	<DOCNO>NCT01905553</DOCNO>
	<brief_summary>To assess effect food pharmacokinetic profile SSP-004184 compare administration fast condition .</brief_summary>
	<brief_title>The Effect Food Bioavailability Single Dose SSP-004184SS Healthy Adult Subjects</brief_title>
	<detailed_description />
	<criteria>Age 1865 year inclusive time consent . The date signing informed consent define begin Screening Period . This inclusion criterion assess Screening Visit . Subject consider `` healthy '' . Healthy status define absence evidence active chronic disease follow detailed medical surgical history , complete physical examination include vital sign , 12lead ECG , hematology , blood chemistry , urinalysis . Serum ferritin &gt; 20ng/mL , hemoglobin &gt; 125g/l , erythrocyte index within normal range clinical laboratory Screening Visit Day 1 : pack cell volume , mean corpuscular volume , mean corpuscular hemoglobin concentration , deem clinically significant investigator . Subject willing comply applicable contraceptive requirement protocol : Male , Female nonchildbearing potential ( defined female postmenopausal [ amenorrhea least 12 consecutive month ] surgically sterile [ hysterectomy , bilateral tubal ligation , bilateral oophorectomy , bilateral salpingectomy ] ) least 6 week poststerilization Nonpregnant , nonlactating female At least 90 day postpartum nulliparous ( female ) . An understanding , ability , willingness fully comply study procedure restriction . Ability provide write , personally sign , date informed consent participate study , accordance International Conference Harmonisation Good Clinical Practice Guideline E6 ( 1996 ) applicable regulation , complete studyrelated procedure . Body mass index 18.530.0kg/mÂ² inclusive . This inclusion criterion assess Screening Visit . Ability swallow investigational product ( multiple capsule 1 time consecutively 1 capsule time ) . A clinically significant history disorder detect medical interview/physical examination cardiovascular , bronchopulmonary , gastrointestinal ( eg , inflammatory bowel disease , chronic diarrhea ) , hepatic , biliary ( include gall bladder removal ) , renal , hematological , endocrine , autoimmune , neurological , psychiatric disease ( include depression ) medical condition capable alter absorption , metabolism , elimination drug ; constitute risk factor take investigational product judgment investigator . Confirmed systolic blood pressure &gt; 139mmHg &lt; 89mmHg , diastolic blood pressure &gt; 89mmHg &lt; 49mmHg . Twelvelead ECG demonstrate QTc &gt; 450msec screening . If QTc exceed 450msec , ECG repeat 2 time average 3 QTc value use determine subject 's eligibility . Subject report food allergy , celiac disease , requirement specific diet ( eg , vegan , vegetarian , low fat ) . Acute illness , judge investigator , within 2 week Day 1 Treatment Period 1 . Known suspected intolerance hypersensitivity investigational product , closely related compound , state ingredient . History thyroid disorder stabilize thyroid medication treatment within 3 month Screening Visit . History alcohol substance abuse within last year . Routine consumption 3 unit caffeine per day subject experience caffeine withdrawal headache . A positive screen alcohol drug abuse Screening Visit . Male subject consume 3 unit alcohol per day . Female subject consume 2 unit alcohol per day . A positive human immunodeficiency virus antibody screen , hepatitis B surface antigen screen , hepatitis C virus antibody screen . Current use medication ( include overthecounter , herbal , homeopathic preparation ) could affect ( improve worsen ) study evaluation accord investigator . Use tobacco form ( eg , smoke chew ) nicotinecontaining product form ( eg , gum , patch ) within 30 day prior Day 1 Treatment Period 1 . Donation blood blood product ( eg , plasma platelet ) within 60 day prior Day 1 Treatment Period 1 . Use another investigational product within 30 day prior Day 1 Treatment Period 1 active enrollment another drug vaccine clinical study . Substantial change eat habit within 30 day prior Day 1 Treatment Period 1 , assess investigator . Prior screen failure , randomization , participation , enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>